Publication: Partial purification and characterization of Trichomonas vaginalis DNA topoisomerase II
Issued Date
2009-09-01
Resource Type
ISSN
01251562
Other identifier(s)
2-s2.0-70349789723
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Southeast Asian Journal of Tropical Medicine and Public Health. Vol.40, No.5 (2009), 877-885
Suggested Citation
Somphong Sithiprom, Songsak Petmitr, Porntip Chavalitshewinkoon-Petmitr Partial purification and characterization of Trichomonas vaginalis DNA topoisomerase II. Southeast Asian Journal of Tropical Medicine and Public Health. Vol.40, No.5 (2009), 877-885. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/27935
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Partial purification and characterization of Trichomonas vaginalis DNA topoisomerase II
Other Contributor(s)
Abstract
DNA topoisomerases regulate conformational changes in DNA topology by catalyzing the breakage and rejoining of DNA strands during the cell cycle. These processes are essential for the multiplication of cells, and inhibition of these reactions stops cell division and cell growth. Drug resistance to Trichomonas vaginalis, a common sexually transmitted protozoan parasite, is increasing worldwide, and DNA topoisomerase II may provide a new target for anti-trichomonal drug development. In this study, T. vaginalis DNA topoisomerase II was partially purified from a large scale axenic culture using fast protein liquid chromatography with a yield of 0.16% and 17-fold purification. The partially purified enzyme was strictly dependent on ATP and Mg2+with optimal concentration of 1 and 10 mM respectively for relaxation activity. T. vaginalis DNA topoisomerase II activity was inhibited by m-amsacrine (m-AMSA) and ofloxacin at minimum inhibitory concentration (MIC) of 250 μM. At this concentration, ciprofloxacin showed incomplete inhibition whereas metronidazole was inactive. DW6, a DNA quadruplex binder, was the most active compound with MIC of 62.5 μM, suggesting the potential for development of such compounds as selective anti-trichomonal drugs in the future.